Taiko Pharmaceutical Co., Ltd. Statistics
Want to see JP:4574 full AI Analyst Report?
Taiko Pharmaceutical Co., Ltd. (4574) Stock Statistics & Valuation Metrics
Total Valuation
Taiko Pharmaceutical Co., Ltd. has a market cap or net worth of JPY 13.02B. The enterprise value is JPY 11.23B.
- Market Cap
- JPY 13.02B
- Enterprise Value
- JPY 11.23B
Share Statistics
Taiko Pharmaceutical Co., Ltd. has 50,636,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 50,636,900
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Taiko Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 4.19%.
- Return on Equity (ROE)
- 0.11
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 4.19%
- Return on Capital Employed (ROCE)
- 0.05
- Revenue Per Employee
- 29.08M
- Profits Per Employee
- 4.20M
- Employee Count
- 220
- Asset Turnover
- 0.52
- Inventory Turnover
- 1.80
Valuation Ratios
The current PE Ratio of Taiko Pharmaceutical Co., Ltd. is 18.92. Taiko Pharmaceutical Co., Ltd.’s PEG ratio is 0.29.
- PE Ratio
- 18.92
- PS Ratio
- 1.97
- PB Ratio
- 1.55
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- 0.29
Income Statement
In the last 12 months, Taiko Pharmaceutical Co., Ltd. had revenue of 6.40B and earned 923.00M in profits. Earnings per share was 18.37.
- Revenue
- 6.40B
- Gross Profit
- 3.48B
- Operating Income
- 459.00M
- Pretax Income
- 958.00M
- Net Income
- 923.00M
- EBITDA
- 724.00M
- Earnings Per Share (EPS)
- 18.37
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Taiko Pharmaceutical Co., Ltd. pays an annual dividend of JPY 13.00, resulting in a dividend yield of 1.27%
- Dividend Per Share
- JPY 13.00
- Dividend Yield
- 1.27%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- 5.24%
Stock Price Statistics
- Beta
- 0.60
- 52-Week Price Change
- -6.14%
- 50-Day Moving Average
- 258.18
- 200-Day Moving Average
- 273.85
- Relative Strength Index (RSI)
- 49.69
- Average Volume (3m)
- 119.01K
Important Dates
Taiko Pharmaceutical Co., Ltd. upcoming earnings date is Nov 13, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 13, 2026
- Ex-Dividend Date
- Dec 29, 2021
Financial Position
Taiko Pharmaceutical Co., Ltd. as a current ratio of 3.36, with Debt / Equity ratio of 9.58%
- Current Ratio
- 3.36
- Quick Ratio
- 2.72
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- -4.75
- Interest Coverage Ratio
- 91.80
Taxes
In the past 12 months, Taiko Pharmaceutical Co., Ltd. has paid 34.00M in taxes.
- Income Tax
- 34.00M
- Effective Tax Rate
- 0.04
Enterprise Valuation
Taiko Pharmaceutical Co., Ltd. EV to EBITDA ratio is 12.06, with an EV/FCF ratio of 0.00.
- EV to Sales
- 1.61
- EV to EBITDA
- 12.06
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Taiko Pharmaceutical Co., Ltd. has JPY 3.17B in cash and marketable securities with JPY 172.00M in debt, giving a net cash position of JPY 2.99B billion.
- Cash & Marketable Securities
- JPY 3.17B
- Total Debt
- JPY 172.00M
- Net Cash
- JPY 2.99B
- Net Cash Per Share
- JPY 59.13
- Tangible Book Value Per Share
- JPY 166.95
Margins
Gross margin is 52.85%, with operating margin of 6.48%, and net profit margin of 10.39%.
- Gross Margin
- 52.85%
- Operating Margin
- 6.48%
- Pretax Margin
- 9.30%
- Net Profit Margin
- 10.39%
- EBITDA Margin
- 13.32%
- EBIT Margin
- 8.97%
Analyst Forecast
The average price target for Taiko Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 13.30%
- EPS Growth Forecast
- 66.38%
Scores
- Smart Score
- ―
- AI Score
- 60
